New pooled data presented in the form of a scientific poster at the American Thoracic Society 2026 International Conference in Orlando suggests that sotatercept may significantly reduce morbidity and mortality risks in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — a particularly challenging population to treat.
The analysis combined data from three phase 3 trials (STELLAR, ZENITH, and HYPERION), covering patients with scleroderma, systemic lupus erythematosus, Sjögren’s syndrome, and rheumatoid arthritis, many of whom were already on double or triple background therapy.
Results showed that sotatercept reduced the risk of a first major morbidity or mortality event compared to placebo. As noted by lead researcher Prof. Rogerio Souza of the University of São Paulo, connective tissue disease-associated pulmonary arterial hypertension is especially complex because patients typically present with multiple concomitant comorbidities alongside the vascular disease itself, making treatment particularly challenging.
Read more at this link on the American Journal of Managed Care